BrainParrot

Health Technology Assessment: A Strategic Tool for Achieving Universal Health Coverage in India

GS2Full notePublished: · Updated:

Source: Yojana, August 2026 · Read the original ↗

Summary

The article reviews Health Technology Assessment India (HTAIn), established under the Department of Health Research, which has completed over 80 studies that have informed pricing, procurement, and adoption decisions — from reducing sickle cell and TB testing costs to enabling portable neonatal hearing screening and AI-assisted TB X-ray interpretation, and revising Health Benefit Packages under government health insurance schemes.

UPSC relevance: GS2/GS3 — Health policy, evidence-based governance, S&T applications

Key facts for Prelims

  • HTAIn was established under the Department of Health Research (DHR), following a recommendation of the National Health Policy, 2017.
  • Article 21 (life, interpreted to include right to health), 38, 39(e) (health of workers), 42 (humane conditions of work/maternity relief), and 47 (duty to raise nutrition/public health standards) are the constitutional anchors cited.
  • Ayushman Bharat–Pradhan Mantri Jan Arogya Yojana (PM-JAY) uses Health Benefit Packages, which HTAIn evidence helps design/revise.
  • National Tuberculosis Elimination Programme (NTEP) and National Programme for Control of Blindness (NPCB) are named user-programmes informed by HTA evidence.

Key points

  • HTAIN established under the Department of Health Research following National Health Policy 2017 recommendations
  • More than 80 studies completed with dozens more underway through a network of technical partners, resource centres, resource hubs, and user departments
  • National Sickle Cell Elimination Mission: HTA evaluations demonstrated point-of-care tests could be procured at affordable prices, generating savings of thousands of crore rupees
  • C-Tb testing for latent tuberculosis: HTA recommendations informed procurement decisions that reduced per-test costs and generated substantial savings
  • Portable neonatal hearing screening devices assessed as cost-effective alternatives, adopted across multiple states
  • Portable ECG machines deployed widely in primary healthcare settings for cardiovascular screening
  • Telemedicine-enabled otoscopes and colour fundus photography for diabetic retinopathy screening adopted through HTA evidence
  • National Tuberculosis Elimination Programme: HTA studies informed adoption of new drug regimens, digital adherence monitoring, and AI-assisted chest X-ray interpretation
  • HTAIN supported revision and rationalisation of hundreds of Health Benefit Packages under government-funded health insurance schemes
  • Six months of trastuzumab therapy for breast cancer evaluated as cost-effective alternative to standard 12-month regimen

Understanding the topic

Data and details

  • HTAIn has completed 80+ studies, with dozens more underway.
  • National Sickle Cell Elimination Mission: HTA-informed procurement generated savings estimated in the thousands of crores of rupees; screening targets 7 crore people in tribal/high-prevalence areas (Madhya Pradesh, Chhattisgarh, Maharashtra, Odisha, Jharkhand, Gujarat, Rajasthan).
  • C-Tb testing for latent TB: HTA recommendations reduced per-test costs, generating substantial programme savings.
  • Breast cancer treatment: HTA evidence found six months of trastuzumab therapy as cost-effective as the standard 12-month regimen.
  • HTAIn supported the revision and rationalisation of hundreds of Health Benefit Packages under government-funded insurance schemes.
  • Technologies validated via HTA for scaled deployment: portable neonatal hearing screening devices, portable ECG machines, telemedicine-enabled otoscopes, and colour fundus photography for diabetic retinopathy.

Static–dynamic linkage

HTA is the operational instance of the static health-economics concept of resource allocation under constraint: given finite public health budgets, which technologies/drugs/diagnostics deliver the greatest health gain per rupee? This bridges to the broader Universal Health Coverage (UHC) debate and to comparative health-financing institutions abroad (e.g., UK's NICE), a recurring GS2 theme on balancing innovation access with fiscal sustainability in health financing.

Syllabus mapping: GS2 — Government policies for health sector development, issues relating to health; GS3 — Science & Technology applications

Background primer

Health Technology Assessment India (HTAIn)

What it is:
India's national mechanism for systematically evaluating health technologies — drugs, diagnostics, devices, and interventions — on clinical effectiveness, cost-effectiveness, safety, equity, and ethical grounds.
Founded:
Established in 2017 under the Department of Health Research (DHR), Ministry of Health and Family Welfare, implementing a recommendation of the National Health Policy, 2017.
Members:
Operates through a network of technical partners, resource centres, and resource hubs (academic/research institutions) that generate evidence for "user departments" — the central and state health programmes that adopt the findings.
Mandate:
Generate evidence to inform pricing, procurement, and programme-adoption decisions, and to support design/rationalisation of Health Benefit Packages under insurance schemes.
Why it matters:
Modelled conceptually on international HTA bodies such as the UK's National Institute for Health and Care Excellence (NICE); created because expanding UHC (via PM-JAY) requires systematic value-for-money evaluation, not just expanded infrastructure spending.

Additional context

The UK's NICE remains the most-cited global reference point for HTA institutions, using similar cost-effectiveness thresholds (cost per quality-adjusted life year) to decide what the National Health Service funds — HTAIn's model follows this broad international template while adapting it to India's programme-based (rather than insurance-based) public health delivery structure. The WHO has also actively promoted HTA institutionalisation as a core UHC-financing tool for low- and middle-income countries, positioning India's HTAIn as part of a broader global trend.

Mains dimensions

  • Evidence-based health financing: HTA shows how systematic cost-effectiveness evaluation (not clinical opinion alone) can directly reduce programme costs (sickle cell, TB) while expanding, not restricting, population coverage.
  • Equity consideration within HTA: evaluations explicitly weigh deployability in tribal/rural/resource-constrained settings (e.g., portable, point-of-care devices), ensuring equity is assessed alongside pure cost-effectiveness — relevant to GS2's social-justice angle on health access.
  • Balancing innovation access and fiscal sustainability: the trastuzumab example (6 vs. 12 months) shows HTA's core tension — new/expensive technologies often provide real but marginal clinical gains, and the policy question is how much the public system should pay for that margin.
  • Institutionalising HTA in procurement: the article implicitly argues for systematising HTA across all public health procurement, not just flagship disease-elimination missions, as a long-term reform priority.
  • Comparative model: contrasting India's programme-centred HTAIn with insurance-centred bodies like UK's NICE sharpens understanding of how health-system structure shapes HTA institutional design.
  • Capacity constraint: 80 studies over roughly a decade, against India's vast health-technology procurement volume, suggests HTAIn's institutional capacity needs to scale significantly to cover a larger share of public health spending.

Possible Mains question

**GS2, 10 marks:** "Examine the role of Health Technology Assessment in achieving Universal Health Coverage in India, with suitable examples from recent disease-elimination programmes."

Related topics

  • Universal Health Coverage and Ayushman Bharat–PM-JAY
  • National Health Policy, 2017
  • NICE (UK) as a comparative HTA model
  • National Health Mission and Health Benefit Package design
  • AI applications in healthcare diagnostics (cross-reference: "Digital India Corporation" article on technology-enabled service delivery)

Topics: GS2Government policies and interventions for development in the health sector; Science and Technology - developments and their applications in everyday life

Yojana August 2026 issue summary →

How we write and check these notes →

All current affairs of 1 August 2026 → · UPSC Current Affairs